Professor Andrew Scott, MD, PhD, (Program Leader at the ONJ Cancer Research Institute, and Director of the PET Centre, Austin Health; formerly Ludwig Institute Director /Memorial-MSKCC)
Andrew is a world renowned expert for clinical translation in oncology leading 10 novel antibodies/recombinant proteins successfully through preclinical development, humanization, production/regulatory compliance, and first-in-human and Phase I/II trials in cancer patients. He has published more than 240 peer-reviewed papers and 20 book chapters, principally in oncology and molecular imaging, Currently Director of the PET Centre at Austin Health, Program leader in the ONJ Cancer Institute, Chairman of the Australian and New Zealand Society of Nuclear Medicine and is President of the World Federation of Nuclear Medicine and Biology
Prof Rodney Hicks, MD (Director of Radiology, Peter MacCallum Cancer Center)
As Director of Radiology, Rod has pioneered the use of PET in the assessment of cancer and has managed over 60,000 PET studies performed in the PET Center he founded in 1996. He has introduced a number of novel imaging techniques that provide enhanced diagnosis and evaluation of cancer behaviour. He is a specialist in RIT therapy and holds numerous national and international research grants. Rod is on 8 editorial boards, has published over 300 peer-reviewed articles and more than 15 book chapters.
Professor David Colcher, MD (Dep Director, Beckman Institute, City-of-Hope NMC)
20 years of experience in developing radiolabelled antibodies for preclinical and clinical applications, through both in vitro and in vivo systems. David is Deputy Director of the Department of Radioimmunotherapy, Director of Radiopharmacy and Professor in the Beckman Research Institute at the City of Hope National Medical centre, Duarte, CA, USA. Dr. Colcher has been a pioneer in the field of developing antibodies to tumour associated antigens.